

DOCKET NO.: RTS-0258

"Express Mail" Label No.: EL263653684US
Date of Deposit: 7-18-2001

#3/K.T.
10/30
H.D.S.
jc971 U.S. PTO
09/910185
07/18/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: C. Frank Bennett et al.

Serial No.: Not yet assigned Group No.: Not yet assigned

Filed: herewith

For: **Antisense Modulation of glioma-associated oncogene-3 Expression**

BOX SEQUENCE

Assistant Commissioner for Patents
Washington DC 20231

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above identified application, no additional fee is required.

Copies of each of the references listed on the attached Form PTO-1449 are enclosed.

Date: July 17, 2001

Respectfully submitted,

Laurel Spear Bernstein
Laurel Spear Bernstein
Registration No. 37,280

ISIS PHARMACEUTICALS, INC.
Carlsbad Research Center
2292 Faraday Avenue
Carlsbad, CA 92008